Content
For Biotech Stocks To Move Higher, This Must Move Lower
Article By:
Tarun Chandra, CFA
Read
Wednesday, May 15, 2024 5:26 AM EDT
While biotechs have significantly lagged behind the broader market, there is reason to be optimistic once inflation-related volatility subsides. IBB and XBI present good vehicles for biotech exposure.
Chart Of The Day: Kewaunee Scientific - New All Time High
Article By:
Jim Van Meerten
Read
Tuesday, May 14, 2024 12:34 PM EDT
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products.
In this article: KEQU
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
Article By:
The Tokenist
Read
Monday, May 13, 2024 2:00 PM EDT
In the last three months, IBRX outperformed NVDA by over 3x.
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Article By:
Lorimer Wilson
Read
Monday, May 13, 2024 1:37 PM EDT
This article highlights the performance last week of the 10 clinical-stage AI-powered and psychedelic compound-based drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio,
Healthcare And Biotech Investing 101: What You Need To Know.
Article By:
Rod Raynovich
Read
Monday, May 13, 2024 4:44 AM EDT
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of demographics and government funding through Medicare.
Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
Article By:
ChinaBio® Today
Read
Saturday, May 11, 2024 3:40 PM EDT
Beijing’s Sino Biological completed its $48 million acquisition of Vancouver-based SignalChem Biotech. Additionally, Biocytogen Pharmaceuticals signed a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG.
Chart Of The Day: ADMA Biologics - Hitting New Highs
Article By:
Jim Van Meerten
Read
Monday, May 6, 2024 11:23 AM EDT
100% technical buy signals
8 new highs and up 7.24% in the last month
110.10+ Weighted Alpha
In this article: ADMA
Why Intellia Therapeutics, Inc. Outpaced The Stock Market
Article By:
Zacks Investment Research
Read
Sunday, May 5, 2024 11:37 AM EDT
Investors will be eagerly watching for the performance of Intellia Therapeutics, Inc. in its upcoming earnings disclosure.
In this article: NTLA
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Article By:
Lorimer Wilson
Read
Sunday, May 5, 2024 12:02 AM EDT
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.
Market Fluctuates Amid Fed Decision And Mixed Corporate Earnings And Economic Signals
Article By:
The Private Banker
Read
Thursday, May 2, 2024 6:30 AM EDT
The U.S. stock markets exhibited mixed responses on Wednesday as investors navigated through a complex landscape of disappointing corporate earnings and a slew of economic data.
Pfizer Q1 Earnings And Revenues Beat Estimates
Article By:
Zacks Investment Research
Read
Wednesday, May 1, 2024 9:40 AM EDT
PFE came out with quarterly earnings of $0.82 per share, beating the our eimate of $0.56 per share. This compares to earnings of $1.23 per share a year ago.
TG Therapeutics Stock Just Rallied 30%: What Happened?
Article By:
Wajeeh Khan
Read
Wednesday, May 1, 2024 9:39 AM EDT
TG Therapeutics Inc (NASDAQ: TGTX) is up 30% on Wednesday even though it reported a wider-than-expected per-share loss for its fiscal first quarter.
In this article: TGTX
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
Article By:
Zacks Investment Research
Read
Sunday, April 28, 2024 4:00 PM EDT
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for both earnings and sales in the first quarter.